Evolus Inc (NASDAQ:EOLS) shares dropped 7.8% during trading on Wednesday . The company traded as low as $12.33 and last traded at $12.70, approximately 1,543,000 shares changed hands during mid-day trading. An increase of 103% from the average daily volume of 759,870 shares. The stock had previously closed at $13.78.
EOLS has been the topic of a number of research reports. ValuEngine raised Evolus from a “hold” rating to a “buy” rating in a research note on Monday, November 4th. Zacks Investment Research raised Evolus from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th. JMP Securities dropped their price objective on Evolus from $35.00 to $30.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 13th. They noted that the move was a valuation call. Mizuho reissued a “buy” rating and issued a $30.00 price objective on shares of Evolus in a research note on Thursday, September 5th. Finally, Leerink Swann initiated coverage on Evolus in a research note on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.36.
The company has a current ratio of 3.66, a quick ratio of 3.28 and a debt-to-equity ratio of 4.53. The firm has a market capitalization of $424.50 million, a price-to-earnings ratio of -8.09 and a beta of 4.44. The stock has a fifty day moving average of $14.90 and a 200-day moving average of $15.53.
Evolus (NASDAQ:EOLS) last issued its earnings results on Monday, November 4th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.33) by $0.55. The company had revenue of $13.17 million during the quarter, compared to analyst estimates of $5.18 million. As a group, equities research analysts forecast that Evolus Inc will post -3.75 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of EOLS. BB&T Securities LLC purchased a new position in shares of Evolus during the second quarter valued at $160,000. Prime Capital Investment Advisors LLC purchased a new position in shares of Evolus during the second quarter valued at $44,000. Point72 Asset Management L.P. purchased a new position in shares of Evolus during the second quarter valued at $4,167,000. HighTower Advisors LLC purchased a new position in shares of Evolus during the second quarter valued at $175,000. Finally, Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Evolus by 2,224.0% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,324 shares of the company’s stock valued at $34,000 after buying an additional 2,224 shares in the last quarter. Institutional investors and hedge funds own 16.94% of the company’s stock.
About Evolus (NASDAQ:EOLS)
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Story: Are sell-side analysts objective?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.